Benzinga | May 14, 2021 06:51AM EDT

Protalix BioTherapeutics Q1 EPS $(0.14) Beats $(0.17) Estimate, Sales $11.32M Beat $10.95M Estimate

Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.17) by 17.65 percent. This is a 240 percent decrease over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $11.32 million which beat the analyst consensus estimate of $10.95 million by 3.38 percent. This is a 47.70 percent decrease over sales of $21.65 million the same period last year.